QIV

BIOLOGICAL7 trials

Sponsors

Merck Sharp & Dohme LLC, Pfizer, BioNTech SE, Institute of Medical Biology, Chinese Academy of Medical Sciences

Conditions

COVID-19Healthy ParticipantsInfluenza BInfluenza Type BInfluenza Viral InfectionsInfluenza aInfluenza, HumanInfluenza, Human Prevention

Phase 1

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza

CompletedNCT05052697

PfizerInfluenza, Human

Start: 2021-09-13End: 2023-01-27Updated: 2024-03-12

Phase I Clinical Trial of Quadrivalent Influenza Virus Split Vaccine

Active, not recruitingNCT06622590

Institute of Medical Biology, Chinese Academy of Medical SciencesInfluenza a, Influenza, Human, Influenza Type B +1

Start: 2024-10-13End: 2025-07-31Target: 180Updated: 2025-01-28

Phase 2

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza

CompletedNCT05596734

BioNTech SECOVID-19, Influenza, Human

Start: 2022-10-28End: 2023-12-28Updated: 2025-07-23

A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).

CompletedNCT05886777

PfizerHealthy Participants

Start: 2023-06-05End: 2024-01-01Updated: 2024-12-18

Phase 3

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)

CompletedNCT03615482

Merck Sharp & Dohme LLCPneumococcal Infections

Start: 2018-09-14End: 2019-06-24Updated: 2024-05-22

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)

CompletedNCT05526716

Merck Sharp & Dohme LLCPneumonia, Pneumococcal

Start: 2022-09-23End: 2023-06-21Updated: 2025-10-29

Phase III Clinical Trial of Quadrivalent Influenza Virus Split Vaccine

Not yet recruitingNCT06800950

Institute of Medical Biology, Chinese Academy of Medical SciencesInfluenza a, Influenza B, Influenza, Human +2

Start: 2025-02-08End: 2025-10-15Target: 4400Updated: 2025-01-30

Related Papers

A Phase 1/2 Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of Nucleoside-Modified Messenger RNA Influenza Vaccines in Healthy Adults

Vaccines2025-04-034 citations

Safety and Immunogenicity of Concomitant Administration and Combined Administration of Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine with or Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age

Vaccines2025-02-053 citations

571. Safety and Immunogenicity of Coadministered Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine With and Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age

Open Forum Infectious Diseases2025-01-29